Medical device technology provider Therma Bright (TSX.V: THRM) (OTC: THRBF) this morning announced that its TherOZap(TM) Technology has been proven successful at inhibiting the Zika virus during in-vitro tests. According to the update, Therma engaged a top Virology Research Laboratory in Canada to study the ability of its TherOZap(TM) technology to inactivate live Zika virus in culture media and to determine inhibition of the Zika virus infection in-vitro in selected cell cultures. Study researchers stated that, “the in-vitro testing has shown that a short heat pulse from the TherOZap(TM) device dramatically inhibits the production of infectious Zika virus in multiple cell types.” The results demonstrated that TherOZap(TM), which utilizes specialized materials, coatings and heat, was able to limit Zika virus (“ZIKV”) cell culture replication. “We are extremely pleased with the test results of our patent pending TherOZap(TM) technology to inhibit the Zika virus,” Therma Bright CEO Rob Fia said in the news release. “We look forward to testing our technology further and to potentially investigate other applications of the TherOZap(TM) technology against other mosquito borne diseases. We will identify partners to work with in these new indications and will seek non-dilutive funding to help fund the research in these new areas.”
To view the full press release, visit http://nnw.fm/Fu9mE
About Therma Bright Inc.
Therma Bright is a progressive medical-device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of the company’s philosophy, as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The company’s breakthrough proprietary technology delivers effective, noninvasive and pain-free skin care. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The company received approval for the above claims from FDA (United States) in 1997. For more information, visit the company’s website at www.ThermaBright.com.
NOTE TO INVESTORS: The latest news and updates relating to THRBF are available in the company’s newsroom at http://nnw.fm/THRBF
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]